Recombinant Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein
Beta LifeScience
SKU/CAT #: BLK-00673P-100UG

Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein
Beta LifeScience
SKU/CAT #: BLK-00673P-100UG
Collections: Fc receptors, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGARGVGK peptide. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGARGVGK |
Target Symbol | HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer |
Species | Human |
Expression System | HEK293 |
Tag | C-His-Avi |
Expression Range | Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M)and VVVGARGVGK peptide |
Mol. Weight | The protein has a predicted MW of 50.30 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |